gilead sciences yeztugo - Search News

News

FDA, HIV and Gilead

The Jerusalem Post on MSN · 9h

FDA approves Yeztugo: Gilead's new twice-yearly HIV prevention injection

He affirmed that the new drug "could take the epidemic to the history books," according to Mother Jones.Yeztugo, based on the molecule lenacapavir, offers a more effective and less invasive prevention method,

Yahoo Finance · 2d

Gilead Sciences (NasdaqGS:GILD) Gains FDA Approval For Yeztugo As PrEP HIV Option

Gilead Sciences (NasdaqGS:GILD) recently achieved FDA approval for Yeztugo, a significant step in HIV prevention as the first twice-yearly PrEP option in the U.S., supported by strong Phase 3 data. Although the company reported a return to profitability in its latest earnings,

BioPharma Dive · 3d

FDA approves twice-yearly shot of Gilead drug for HIV prevention

The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market dominated by oral medicines.

10hon MSN

Here’s what everyone should know about this new HIV prevention shot

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

Fierce Pharma3d

FDA signs off on Gilead's landmark long-acting PrEP med, signaling new era in HIV prevention

With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results